Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
SourceBreast Cancer Research, 21, 1, (2019), article 97
Article / Letter to editor
Display more detailsDisplay less details
Breast Cancer Research
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.